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Abstract
During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties
of individual bones. Among these, TGF-b has been shown to developmentally regulate bone mass and bone matrix
properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical
environment are distinct from those that regulate bone development. In addition, despite advances in understanding the
roles of TGF-b signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF-b signaling on bone remain
unclear. To examine the role of TGF-b in the maintenance of the postnatal skeleton, we evaluated the effects of
pharmacological inhibition of the TGF-b type I receptor (TbRI) kinase on bone mass, architecture and material properties.
Inhibition of TbRI function increased bone mass and multiple aspects of bone quality, including trabecular bone
architecture and macro-mechanical behavior of vertebral bone. TbRI inhibitors achieved these effects by increasing
osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore,
they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which
antagonizes osteoclast differentiation. Through these anabolic and anti-catabolic effects, TbRI inhibitors coordinate changes
in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that
collectively increase bone fracture resistance. Therefore, TbRI inhibitors may be effective in treating conditions of skeletal
fragility.
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Introduction
In skeletal development, each bone is formed with a distinctive
size, geometry, architecture, and material properties. Among the
many growth factors and hormones involved in this process [1–3],
transforming growth factor-b (TGF-b) is sequestered at high levels
in bone matrix and is a critical regulator of osteogenesis [4]. Bone
mass is dramatically affected by developmental manipulation of
TGF-b signaling in genetically modified mouse models [5–9]. In
addition to bone mass, TGF-b regulates bone matrix material
properties, which impact the ability of bone to resist fracture [10].
However, little is known about the role of TGF-b in the post-natal
skeleton, which responds to changes in bone or the environment to
retain or improve bone quality, fundamentally defined as the
ability to resist bone fracture [11].
The effects of postnatal manipulation of TGF-b signaling on
bone mass and quality are difficult to predict based on
developmental studies. For example, osteoporosis and bone
fragility are observed in mice with increased TGF-b production
[6], as well as in those that are deficient in Smad3 [8,9], a key
TGF-b effector. Conversely, other mouse models with reduced
TGF-b signaling have increased bone mass and quality [7,10]. In
addition, the roles of TGF-b on the proliferation, differentiation,
and apoptosis of cells in both the osteoblast and osteoclast lineages
have been extensively studied [4,12–14]. In spite of this wealth of
information, the net effect of postnatal TGF-b signaling on bone
remains unknown.
The recent development of specific inhibitors of the TGF-b type
I receptor (TbRI) kinase that block most if not all TGF-b signaling
events [15–17] now enables an investigation of this fundamental
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5275question. ATP-competitive inhibitors of the TbRI kinase, such as
SD-208, can effectively limit TGF-b-mediated lung fibrosis and
tumorigenesis in vivo at doses that are too low to exert non-specific
effects on other kinases [17–20]. Since such inhibitors are in
clinical trials for cancer and other disorders, it is crucial to define
the effects of TGF-b blockade on the skeleton.
Maintenance of the postnatal skeleton depends on the
functional coordination between bone-depositing osteoblasts and
bone-resorbing osteoclasts [21]. Both cell populations express and
respond to TGF-b, and TGF-b has been suggested to couple
osteoblast and osteoclast activity [4]. TGF-b promotes osteopro-
genitor proliferation and inhibits terminal osteoblast differentia-
tion, in part by repressing the function of osteogenic transcription
factor Runx2 [22]. TGF-b also regulates osteoblast expression of
osteoclast regulatory factors m-CSF, RANKL, and OPG [23–25],
whereas resorbing osteoclasts release and activate matrix-bound
latent TGF-b, which feeds back to modulate osteoblast and
osteoclast function [26–28]. Because the effects of TGF-b on
osteoblast and osteoclast function are dynamic, dose-dependent,
and specific for each cell type and stage of differentiation [4,12–
14], prior studies do not indicate how the cell types present in
mature bone will respond to a systemic alteration in TGF-b
signaling.
In the current study, we found that the TbRI kinase inhibitor,
SD-208, affects osteoblast and osteoclast function to coordinately
regulate several bone parameters, resulting in increased bone mass
and trabecular bone volume, as well as increased mineral
concentration and elastic modulus of bone matrix. This was
associated with an increased resistance to vertebral fracture. These
results suggest that pharmacologic inhibition of TGF-b signaling
may have therapeutic utility in a variety of bone diseases
characterized by poor bone quality, low bone mass and a
propensity to fracture.
Results
Pharmacologic inhibition of the TbRI kinase increases
bone mineral density
To determine the effects of pharmacologic inhibition of TGF-b
signaling on bone, mice were treated for 6 weeks with either of two
doses of SD-208, a small molecule that blocks ATP binding to the
type I TGF-b receptor to specifically inhibit its kinase activity [17].
The 20 mg/kg SD-208 dose was chosen to achieve specific
inhibition of the TbRI kinase, whereas the 60 mg/kg dose was
chosen to achieve a maximal response with minimal inhibition of
other pathways [19]. Using mice that express luciferase under the
control of a TGF-b-responsive Smad binding element (SBE-Luc
mice) [29], we confirmed the ability of SD-208 to inhibit
endogenous and exogenously applied TGF-b function in bone in
vivo and ex vivo (Fig. 1a, 1b). As expected, the well-established
TGF-b-inducible expression of PAI-1 [30] was inhibited by SD-
208 in calvarial explants, whereas the expression of reported
targets of TGF-b repression, Runx2 and osteocalcin [22], was
induced by SD-208 (Fig. 1c).
Longitudinal examination of the bone mineral density (BMD)
by dual energy X-ray absorptiometry (DXA) showed the normal
increase in BMD between 1 and 2.5 months of age. Accordingly,
vehicle-treated male and female mice showed an increase of
21.8% and 29.6%, respectively, in whole body BMD after 6 weeks
(Fig. 2a, 2b). Although low dose SD-208 did not affect whole body
BMD, both male and female mice treated with high dose SD-208,
showed significantly greater bone accrual over the same time
period, with an additional 4.12% increase in male (p,0.001) and
5.2% increase in female (p,0.001) whole body BMD. The SD-
208-induced increase in whole body BMD was comparable to that
observed following an 8-week treatment with bisphosphonates,
which can increase whole body BMD by 5% [31].
More pronounced effects were apparent in the tibia and femur,
where the BMD was already significantly increased within 3 weeks
of SD-208 treatment relative to vehicle-treated controls (Fig. 2c–
2f). After 6 weeks, SD-208 significantly increased the BMD in
male mice by 20% in the tibia (p,0.001), 14.8% in the femur
(p,0.001) and 8.9% in the lumbar spine (p,0.01) relative to
vehicle-treated mice. SD-208 increased the tibial, femoral and
lumbar spine BMD in female mice by 16.3% (p,0.001), 11.4%
(p,0.01) and 17.9% (p,0.001), respectively. Dose-dependent
increases in BMD were most apparent in the femur (Fig. 2e, 2f).
Thus, systemic pharmacologic inhibition of TGF-b signaling
increases the BMD.
Inhibition of the TbRI kinase increases trabecular bone
To determine if the increased BMD resulted from changes in
cortical or trabecular bone, dissected femora and tibiae were
analyzed using micro-computed tomography (micro-CT). Recon-
structed images of trabecular bone in the distal femur showed a
dose-dependent increase in trabecular bone volume following 6
weeks of SD-208 treatment in both male and female mice (Fig. 3a).
This increase in trabecular bone was noted in the secondary
spongiosa and did not extend to the diaphysis (Figure S1). At the
high dose, SD-208 increased the femoral trabecular bone volume
of male and female mice by 57.6% and 264%, respectively (Fig. 3b,
Table 1). Remarkably, high-dose SD-208 increased the trabecular
density of male and female femora by 192% and 581%,
respectively (Fig. 3c). Increases in trabecular number and thickness
were associated with a corresponding decrease in trabecular
separation following treatment with SD-208 (Fig. 3d, 3e, Table 1).
As shown by these and other parameters, SD-208 greatly
improved trabecular bone microarchitecture in male and female
femora and tibiae (Table 1). In contrast, SD-208 caused no
significant differences in measured cortical bone parameters
(Table 2). Therefore, the effect of 6 weeks of pharmacologic
inhibition of TbRI function on BMD appears to be specific to the
trabecular bone.
Inhibition of TbRI affects both osteoblasts and
osteoclasts
Increased BMD may be due to increased osteoblast activity,
reduced osteoclast activity or both. Quantitative histomorphom-
etry confirmed the SD-208 dose-dependent increase in trabecular
bone that was observed by micro-CT (Fig. 4a). The significantly
increased bone volume (Fig. 4b) was accompanied by a TbRI
inhibitor dose-dependent increase in osteoblast number (Fig. 4c).
Importantly, even the most specific low dose of SD-208 (20 mg/
kg) caused significant increases in male and female bone volume
and osteoblast numbers (p,0.05). In addition, the osteoclast
numbers were reduced in the femora of SD-208 treated mice
(Fig. 4d). Bones from male mice treated with the highest dose of
SD-208 had twice as many osteoblasts and half as many osteoclasts
as the vehicle-treated controls (Fig. 4).
These data suggest that inhibition of TGF-b signaling increases
bone mass by enhancing bone formation and inhibiting bone
resorption. Dynamic histomorphometry revealed that SD-208
stimulates a dose-dependent increase in the mineral apposition
rate and bone formation rate in male mice (Fig. 4e, 4f). Female
mice showed the same trend. Collectively, these analyses
demonstrate that TbRI inhibitors increase bone mass in mature
mice via anabolic and anti-catabolic mechanisms.
TbRI Inhibition in Mature Bone
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inhibits osteoclast differentiation
To determine if the changes in osteoblast and osteoclast
numbers and activity resulted from changes in cell differentiation,
bone marrow stromal cells that were isolated from vehicle- and
SD-208-treated mice were examined ex vivo in osteoblast or
osteoclast differentiation assays (Fig. 5a–5c). In vivo exposure to
SD-208 enhanced the osteoblast differentiation (CFU-Ob, Fig. 5a)
with no detectable effect on osteoprogenitor recruitment (CFU-F,
Fig. 5b). Conversely, marrow stromal cells from mice treated with
SD-208 formed fewer multinucleated cells that express the
functional osteoclast marker TRAP (Fig. 5c). Thus, in vivo
inhibition of TbRI with SD-208 promotes osteoblast differentia-
tion and inhibits osteoclast differentiation.
To investigate the effect of TbRI inhibitors on the expression of
osteoblast and osteoclast regulatory factors, we utilized primary
calvarial osteoblasts, which retain the capacity to differentiate into
mineralizing osteoblasts, and have an intact autocrine TGF-b
Figure 1. SD-208 inhibition of TGF-b function in vivo. Five hours after TGF-b administration, SBE-Luc mice showed increased bioluminescence
on the dorsal and ventral surfaces of the head where relatively little superficial tissue covers skeletal elements (calvarial bone and jaws) (a). Mice
pretreated with SD-208 showed less basal and TGF-b-inducible luminescence than vehicle-treated controls (a, lower panels). SD-208 also inhibited
reporter activity in SBE-Luc mouse calvarial explants cultured overnight with TGF-b (b). SD-208 treatment of calvarial explants inhibits expression of
the TGF-b-inducible gene, PAI-1 [30], but induces expression of Runx2 and osteocalcin, osteoblast marker genes that are targets of TGF-b repression
[22].
doi:10.1371/journal.pone.0005275.g001
TbRI Inhibition in Mature Bone
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(Fig. 1c), another ATP-competitive TbRI kinase inhibitor,
SB431542, inhibits the expression of the TGF-b-inducible gene,
PAI-1 [30], in primary calvarial osteoblasts (Fig. 5d). As shown
previously [22], Runx2 expression was reduced after 48 h of
treatment with added TGF-b (Fig. 5d). In contrast, TbRI
inhibitors induce Runx2 expression, consistent with the increased
osteoblast numbers, bone formation rate, and osteoblast differen-
tiation potential observed in SD-208-treated mice (Fig. 4c, 4f,
5a, 5d).
RANK ligand (RANKL) promotes osteoclast differentiation,
function and survival [21]. After 48 h of treatment, TbRI
inhibitors reduced the expression of RANKL mRNA by
approximately 50% compared with the mRNA levels observed
in vehicle-treated primary calvarial osteoblasts (Fig. 5e). The
reduced expression of this osteoclastogenic factor is consistent with
the decreased osteoclast numbers and differentiation capacity
observed in SD-208-treated mice (Figs. 4d and 5c). However,
RANKL function is antagonized by osteoprotegerin, the expres-
sion of which is also reduced by TbRI-I treatment. Similar results
were observed after 2 h of TbRI-I treatment (data not shown).
Though the inhibition of TGF-b signaling impacts both of these
critical regulators of osteoclast differentiation and function, the
relative RANKL/OPG ratio is unchanged. Therefore, the effect of
inhibition TbRI function on other factors which regulate
osteoblast and osteoclast function was investigated.
Recently, ephrin B2 and EphB4, a transmembrane ligand and
receptor respectively, have been implicated as factors that couple
osteoblast and osteoclast activities in bone metabolism [32].
Bidirectional signaling between ephrin B2, expressed by osteo-
blasts and osteoclasts, and EphB4 on osteoblasts increases
osteoblast differentiation and inhibits osteoclast differentiation
[32]. However, the ability of TGF-b to control ephrin signaling in
bone metabolism has not been reported. Inhibition of TbRI
function significantly increased the expression of both ephrin B2,
the ephrin that inhibits osteoclast differentiation (Fig. 5f), and
EphB4, the Eph receptor that induces osteoblast differentiation.
TGF-b signaling crosstalk with the ephrin pathway may contribute
to the anabolic and anti-catabolic effects of SD-208 on bone,
though additional experiments are needed to establish a functional
link. By affecting osteoblast and osteoclast differentiation, numbers
and activity (Figs. 4c–f, 5a, 5c), the TbRI inhibitor dramatically
shifts bone toward a state of metabolic anabolism.
TbRI inhibitors increase bone matrix mineral
concentration, material properties and fracture resistance
The net effect of TbRI inhibitors on bone is increased BMD,
which reflects both bone mass and mineral concentration (Fig. 2).
With the monochromatic light from synchrotron radiation, X-ray
tomographic microscopy (XTM) permits direct quantification of
the mineral concentration of bone matrix with an 8 mm resolution
[33]. Analyses of femoral bone showed that SD-208 treatment
resulted in a higher degree of mineralization of bone matrix
(Fig. 6a). The SD-208-dependent increase in mineral concentra-
tion was evident in both the diaphysis and epiphysis (data not
shown), suggesting that the mineralization of both cortical and
trabecular bone were affected.
Mineral concentration is a major determinant of bone matrix
material properties [34]. Using nanoindentation, material prop-
erties such as the elastic modulus and hardness of bone matrix can
be determined independently of changes in bone mass or structure
[35,36]. We have previously used this approach to demonstrate
that TGF-b signaling in osteoblasts regulates the elastic modulus
and hardness of bone matrix in genetically-modified mice [10].
Treatment of mice with SD-208 increased the elastic modulus of
cortical bone relative to vehicle-treated controls. Although the
measured modulus values in each group overlapped, more than
half of the measurements in vehicle-treated bone were below
28 GPa, whereas less than a quarter of the values measured in SD-
208-treated mice were in the same range (Fig. 6b).
Treatment with the TbRI inhibitor SD-208 affects bone on
several levels, including bone mass (Figs. 2–4), bone mineral
concentration and bone matrix material properties (Figs. 6a, 6b).
These observations led us to perform macro-mechanical testing to
evaluate the ability of SD-208-treated bones to resist fracture.
Compression testing of vertebrae showed that inhibition of the
TbRI kinase increased the load-to-failure relative to vehicle-
treated controls (Fig. 6c, Table 3). When the femora were tested
using notched or unnotched three-point bending, SD-208-
dependent differences in peak load, stiffness, or fracture toughness
were not observed (Table 4). The increased load-to-failure of SD-
208-treated vertebral bone, but not femoral bone, is entirely
consistent with the increase in trabecular but not cortical bone
volume after 6 weeks of SD-208 treatment. Together these data
demonstrate that TGF-b inhibitors drive functionally significant
and coordinated increases in trabecular bone mass, mineral
concentration and bone matrix material properties.
Discussion
Here we explored the role of TGF-b signaling in postnatal bone
by systemic administration of a TbRI inhibitor to mature mice.
Pharmacologic inhibition of TGF-b signaling resulted in dose-
dependent increases in BMD, trabecular microarchitecture, bone
matrix elastic modulus and mineral concentration. These
coordinated changes in bone mass and parameters of bone quality
improved the ability of vertebral bone to resist fracture. By
targeting key regulatory pathways in osteoblasts and osteoclasts,
TbRI inhibitors increased the number of osteoblasts and the bone
formation rate, while reducing osteoclast numbers. Therefore,
TbRI inhibition elicits both anabolic and anti-catabolic activities
to improve bone quality.
The TbRI inhibitor-dependent increase in tibial BMD
exceeded the physiologic increase in BMD over this time period
or those induced by comparable regimens utilizing clinically
available bisphosphonates or PTH [31,37]. TbRI inhibitors may
have more profound effects since they both stimulate bone
formation and inhibit bone resorption, rather than the uncoupled
effects of PTH to stimulate osteoblast activity or bisphosphonates
to inhibit osteoclast activity. The effects of the TbRI inhibitor on
adult bone are consistent with the developmental bone phenotypes
of mice with partial inhibition of TGF-b/Smad signaling, as
observed in Smad3+/2 mice or DNTbRII mice that express a
dominant negative TGF-b type II receptor in osteoblasts [7,10]. In
contrast, more complete inhibition of TGF-b signaling in
Figure 2. Pharmacologic TbRI inhibition increases BMD. DXA was used to measure BMD longitudinally for male (a, c, e, g) and female mice (b,
d, f, h) treated with or without the TbRI inhibitor SD-208 at 20 mg/kg or 60 mg/kg. SD-208 treatment at the 60 mg/kg dose caused an increase in
total body (a, b) tibia (c, d), femur (e, f), and lumbar spine (g, h) BMD. SD-208 at the 20 mg/kg dose increased femoral BMD in female mice (f). Data
represent mean6SEM (p,0.05, as determined by two-way analysis of variance (ANOVA).
doi:10.1371/journal.pone.0005275.g002
TbRI Inhibition in Mature Bone
PLoS ONE | www.plosone.org 5 April 2009 | Volume 4 | Issue 4 | e5275Figure 3. Pharmacologic TbRI inhibition increases trabecular bone volume. Micro-CT images show increased femoral trabecular bone
volume following SD-208 treatment in male and female mice, relative to vehicle-treated controls (a). Quantitative analyses show that SD-208
increased trabecular bone volume (BV/TV, fraction) (b), connectivity density (c), and trabecular number (d), but decreased trabecular spacing (e) in
male and female femora. Data represent mean6SEM (p,0.05, as determined by one-way ANOVA Newman-Keuls multiple comparison test).
doi:10.1371/journal.pone.0005275.g003
TbRI Inhibition in Mature Bone
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mass and poor bone quality, which may result, in part, from the
significant systemic effects of Smad3 and TGF-b1 deletion [5,8,9].
Some effects of TbRI inhibition on bone resulted from the
reduction in osteoclast numbers and differentiation potential in
SD-208-treated mice (Figs. 4d, 5c). This in vivo response is striking
because TGF-b has been shown to inhibit and promote osteoclast
differentiation in vitro, depending on the timing, dose and
experimental cell population [12]. TGF-b can act by binding
directly to its receptors on osteoclasts and their progenitors, or by
acting on osteoblasts to regulate the expression of osteoclast
regulatory factors, such as RANKL and OPG [6,7,23–25,38–40].
Though the current study does not explore the extent to which
SD-208 affects osteoclasts directly or indirectly through osteoblast-
dependent mechanisms, SD-208 can directly inhibit osteoclast
function in a purified osteoclast precursor population (Guise,
personal communication). In addition, TbRI inhibitors regulated
osteoblast expression of osteoclast regulatory factors such as
RANKL, OPG, ephrin B2 and EphB4 (Fig. 5). Likely, a
combination of direct and indirect mechanisms is responsible for
the anti-catabolic and anabolic effects of TbRI inhibitors in vivo.
Treatment of mice with TbRI inhibitors resulted in increased
osteoblast numbers and differentiation, and increased bone
formation. Consistent with these data, reduced TGF-b signaling
in Smad3+/2 mice or DNTbRII mice also relieves the
suppression of osteoblast differentiation by TGF-b, which is
exerted by Smad3 and histone deacetylases [22,41], thereby
contributing to increased BMD [7,10]. The increased osteogenic
differentiation in response to TbRI inhibitors may also reflect a
decrease in repression of BMP signaling by the inhibitory Smad6
[42]. Although changes in Smad6 expression were not observed in
our experimental conditions, the BMP antagonist, Noggin,
reversed some effects of TbRI inhibitors on gene expression (data
not shown), affirming the previous observation that increased
BMP signaling contributes to the osteogenic activity of TbRI
inhibitors [42]. Therefore, despite the ability of TGF-b to promote
or inhibit specific stages of osteoblast differentiation [13], the net
effect of TbRI inhibitors on osteoblasts in vivo is to increase bone
formation.
Ultimately, the ability of bone to resist fracture is the most
clinically desirable outcome [11]. TbRI inhibition increased the
peak load that vertebral bone can sustain prior to fracture, in part
due to the potent anabolic effect of TbRI inhibitors on trabecular
bone. Although a 6-week treatment with TbRI inhibitors was
insufficient to increase cortical bone mass or geometry, it
significantly increased the mineralization and material properties
of cortical bone matrix, when measured using high-resolution
XTM and nanoindentation. These data suggest that optimization
of the dose or duration of therapy may result in detectable changes
in cortical bone mass and macromechanical behavior. Further-
more, our data indicate that TGF-b signaling helps define bone
matrix material properties postnatally as it does in development
[10], although the effect was more modest than that observed in
genetically modified mice. Although the elastic modulus of bone
matrix often correlates with mineral content [1], Smad3 also
regulates material properties independently of mineralization, as
has recently been shown in skin [43]. The mechanisms by which
TGF-b regulates the material properties of extracelullar matrices
remain unknown.
In conclusion, pharmacologic inhibition of TGF-b signaling in
postnatal bone increases bone quality. Coupling of osteoblast and
osteoclast activity may be critical for the ability of TGF-b to
coordinately control bone mass, architecture, and the material
properties of bone. Therefore, therapies that produce a reliable
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PLoS ONE | www.plosone.org 7 April 2009 | Volume 4 | Issue 4 | e5275reduction in TGF-b signaling may have significant clinical benefit
in the treatment of diseases characterized by low bone mass and
bone fragility. However, TbRI-inhibition may be counter-
indicated for the treatment of existing bone fractures, where
TGF-b plays a role in fracture repair. Additional studies
evaluating the efficacy and potential sex-specificity of the mature
skeletal response to TbRI inhibitors, particularly in ovariecto-
mized animals, would be needed to determine their potential
therapeutic value for post-menopausal osteoporosis. Careful
consideration of safety is essential, given the critical role of
TGF-b in normal physiological processes including the control of
cell proliferation, differentiation, and apoptosis in many tissues.
Materials and Methods
Ethics Statement
In all studies, mice were handled and euthanized in accordance
with approved institutional, national and international guidelines.
TbRI inhibitor treatment
Four-week old male and female C57BL/6 mice were treated for
6 weeks with vehicle (1% methylcellulose) or SD-208 (20 mg/kg
once daily or 60 mg/kg twice daily) by gavage. As described, SD-
208 is a specific inhibitor of the TGF-b type I receptor, developed
by Scios, Inc. [17]. Based on the mouse monitoring parameters of
our treatment protocol, no adverse effects of SD-208 on mouse
health were detected during the study. At 10 and 3 days prior to
euthanasia, an intraperitoneal injection of calcein (Sigma C-0875,
0.02 mg/g) was administered to all mice. Forelimbs, hindlimbs,
and spines were collected. For studies using SBE-luciferase mice
[29], mice were treated with vehicle or 60 mg/kg SD-208 as above
for 3 days, prior to an intraperitoneal injection of TGF-b1 (10 mg/
kg). Five hours later, mice were administered luciferin (150 mg/kg)
intraperitoneally, anaesthetized with isoflourane, and imaged
10 minutes later using a bioluminescence imaging system (Xeno-
gen).
Bone mineral density (BMD) measurement
BMD was measured using a PIXImus mouse densitometer (GE
Lunar II, Faxitron Corp., Wheeling, IL) (N=15/group). Total
body measurement was performed excluding the calvarium,
mandible and teeth. Regions of interest were defined as the distal
femur and proximal tibia just beneath the growth plate
(12612 pixels) and the lower lumbar spine (20650 pixels). Values
were expressed as percentage change in BMD over the
pretreatment scan.
Histomorphometry
For demineralized bone histomorphometry, tissues were fixed
for 48 h in 10% formalin, demineralized in 10% EDTA for 2
weeks, and embedded in paraffin to generate 3.5 mm longitudinal
sections. Trabecular bone volume of the secondary spongiosa
(BV/TV%) and osteoblast number (N.Ob/high power field) were
measured on hematoxylin and eosin stained sections of the distal
femur, proximal tibia, and lumbar vertebrae (N$12 mice/group).
Tartrate resistant acid phosphatase (TRAP) stained sections were
used to quantify osteoclast number (N.Oc/BS/mm). Dynamic
bone histomorphometry was performed on 7 mm thick sections of
mineralized lumbar vertebrae embedded in methylmethacrylate
using standard procedures. The mineral apposition rate (MAR,
mm/day) and bone formation rate (BFR/BS, mm
3/mm
2/day) were
measured on vertebral trabecular bone using fluorescence
microscopy to visualize calcein labels as described [44].
Micro-computed tomography (micro-CT)
Formalin fixed tibiae and femora were imaged with micro-CT
using a microCT-40 (Scanco Medical AG, Bassersdorf, Switzer-
land) using a voxel size of 12 mm in all dimensions (N$12 mice/
group). The region of interest comprised 240 transverse CT slices
representing the entire medullary volume with a border lying
approximately 100 mm from the cortex [45]. Morphometric
variables were computed using direct, three-dimensional tech-
niques that do not rely on assumptions about the underlying
structure. Fractional bone volume (BV/TV, Fraction) and
architectural properties of trabecular reconstructions, apparent
trabecular thickness (Tb.Th., mm), trabecular number (Tb.N.,
mm
21), trabecular spacing (Tb.Sp., 1/mm), and connectivity
density (Conn.D., mm
23) were calculated as described [46].
Cortical bone assessment by micro-CT
The CT images of the mid-diaphysis of the tibia were
segmented into bone and marrow regions by applying a visually
chosen, fixed threshold for all samples, after smoothing the image
with a three-dimensional Gaussian low-pass filter. The outer
Table 2. Cortical bone structural parameters are not affected by TbRI inhibition.
Male Female
Vehicle SD-208 20 mg SD-208 60 mg Vehicle SD-208 20 mg SD-208 60 mg
Cort. CSA 0.18360.019 0.18260.016 0.17260.007 0.15560.007 0.15660.006 0.15260.003
Cort. Th. 0.20160.005 0.17860.006 0.18660.005 0.18660.011 0.19560.005 0.18860.004
Total CSA 0.32960.038 0.34660.035 0.40560.025 0.28160.017 0.28560.015 0.28160.007
Perios. Perim. 1.05760.098 1.20260.081 0.98660.057 0.96460.047 0.97760.045 0.95860.017
Diam. Mid
Shaft
0.59260.017 0.54660.017 0.57760.004 0.55460.012 0.55560.005 0.56060.010
Med. Area 0.18260.040 0.21860.098 0.21460.019 0.10560.009 0.10960.008 0.11060.005
Endosteal
Perim
0.76160.078 0.89160.233 0.72960.055 0.57160.049 0.59660.038 0.61460.020
Mid Diam 0.44760.054 0.42760.077 0.55160.013 0.35260.008 0.35160.003 0.34360.011
Micro-computed tomography was used to assess several quantitative parameters of cortical bone structure. The mean values and standard deviations are presented
here.
doi:10.1371/journal.pone.0005275.t002
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PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e5275Figure 4. Pharmacologic TbRI inhibition increases osteoblast numbers but reduces osteoclast numbers. Representative H&E stained
sections of femoral bone show the SD-208-dependent increase in trabecular bone in male and female mice (a). Histomorphometry shows that SD-208
increases trabecular bone volume in the femur (b) and tibia (data not shown), as well as osteoblast number (c) in a dose-dependent manner for male
and female mice. Osteoclast numbers are reduced by SD-208 (60 mg/kg) in male mice (d). Dynamic histomorphometry of male mouse lumbar
vertebrae shows that SD-208 treatment (60 mg/kg) increased mineral apposition rate (MAR) (e) and bone formation rate (BFR) (f). Data represent
mean6SEM (*p,0.05, **p,0.01, ***p,0.001, as determined by one-way ANOVA Newman-Keuls multiple comparison test).
doi:10.1371/journal.pone.0005275.g004
Figure 5. TbRI inhibition promotes osteoblast differentiation and bone deposition but inhibits osteoclast differentiation. Bone
marrow isolated from male and female mice treated with SD-208 (60 mg/kg) has increased numbers of osteoblast colony forming units (CFU-OB) (a)
with no change in the number of colony forming units (CFU-F) (b). The number of TRAP-positive multinucleated cells (TRAP+ MNC) is lower in
cultures from SD-208 treated mice than from vehicle-treated controls (c). Primary calvarial osteoblasts treated with TbRI-inhibitor SB431542 (10mM) or
vehicle for 48 h show altered mRNA expression of PAI-1 (d) and several osteoblast and osteoclast regulatory factors including Runx2 (d), RANKL and
OPG (e), and ephrinB2 and EphB4 (f). Data represent mean6SEM (*p,0.05, **p,0.01, ***p,0.001, as determined by unpaired t-test).
doi:10.1371/journal.pone.0005275.g005
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PLoS ONE | www.plosone.org 10 April 2009 | Volume 4 | Issue 4 | e5275contour of the bone was found automatically with the built-in
Scanco iterative contouring tool. Total area (TA) was calculated
by counting all voxels within the contoured bone area, (BA) by
counting all voxels that were segmented as bone, and marrow area
(MA) was calculated as TA-BA. This calculation was performed on
all 30 slices (1 slice=12.5 mm), using the average for the final
calculation. The outer and inner perimeter of the cortical midshaft
was determined by a three-dimensional triangulation of the bone
Figure 6. TbRI inhibitors increase bone mechanical and material properties. Analysis of each pixel from XTM scans of femora show that SD-
208 (60 mg/kg) increases bone matrix mineral concentration with a mean of 1.90 g/cm
3+/20.066, relative to a mean mineral concentration of 1.54 g/
cm
3+/20.069 for vehicle-treated controls (p,0.05, as determined by unpaired t-test) (a). Analysis of elastic modulus values from nanoindents applied
to tibial cortical bone showed a similar shift (p,0.05) (b). Unconfined compression testing of vertebrae from male mice treated with vehicle or SD-208
(60 mg/kg) shows an increased peak load-to-failure following TbRI inhibition (p,0.05) (e).
doi:10.1371/journal.pone.0005275.g006
TbRI Inhibition in Mature Bone
PLoS ONE | www.plosone.org 11 April 2009 | Volume 4 | Issue 4 | e5275surface (BS) of the 30 slices, and cortical parameters were
calculated as described [47].
Marrow stromal cell differentiation assays
Bone marrow stromal cells were flushed from 6 femora and
tibiae per treatment group, collected by centrifugation (1500 rpm,
10 minutes), resuspended (aMEM, 10% FCS), and incubated for
2 h at 37uC. For osteoblast assays, cells were cultured in aMEM,
15% FBS, 50 mg/ml ascorbic acid, and 10 mM b-glycerophos-
phate. The number of alkaline phosphatase-positive osteoblast
progenitor forming colonies (CFU-F) and Alizarin Red-positive
osteoblast forming colonies (CFU-OB) was quantified microscop-
ically after 9 or 28 days of culture, respectively, as described
[48,49]. For osteoclast progenitor assays, non-adherent cells were
cultured for 6 days in 10% aMEM, 1% FBS and 10
28 M
1a,25(OH)2 vitamin D3. Cultures were fixed and stained for
microscopic quantification of multinucleated (MNC) TRAP+ cells.
Tissue culture, RNA isolation, and quantitative reverse
transcription PCR
Calvarial explants were isolated from 10 day old SBE-Luc mice
and cultured overnight in DMEM supplemented with 10% fetal
bovine serum and 5 ng/ml TGF-b1 in the presence of either
150 nM SD-208 or an equivalent volume of vehicle (1%
methylcellulose). Following culture, explants were moved to media
containing luciferin (150 mg/ml) for immediate visualization of
luciferase reporter activity with a bioluminescent imaging system
(Xenogen). Explants were then crushed in liquid nitrogen using a
mortar and pestle prior to additional tissue disruption in Trizol
with a Omni-GLH homogenizer (Omni Scientific). Following
Trizol extraction, RNA was further purified using RNeasy
columns (Qiagen).
Primary calvarial osteoblasts were isolated from 3 to 5-day old
mice and cultured in osteogenic conditions as described [22]. Cells
were treated with a commercially available TGF-b receptor type I
inhibitory compound suspended in DMSO (SB431542, Sigma) for
48 h. All other cells received an equivalent quantity of DMSO in
the presence or absence of TGF-b (5 ng/ml). Total RNA was
purified using RNAeasy columns (Qiagen) and reverse transcribed
for the analysis of gene expression. Transcripts were amplified
using primers sets for PAI-1 59-AACCAATTTACTGAAAA-
ACTGCACAA-39 (forward) and 59-TCCGGTGGAGACATAA-
CAGATG-39 (reverse), Runx2 59-CCCAGCCACCTTTACC-
TACA-39 (forward) and 59-CAGCGTCAACACCATCATTC-39
(reverse), OPG 59-AGAGCAAACCTTCCAGCTGC-39 (forward)
and 59-CTGCTCTGTGGTGAGGTTCG-39 (reverse), RANKL
59-CACCATCAGCTGAAGATAGT-39 (forward) and 59-CCAA-
GATCTCTAACATGACG-39 (reverse), EphrinB2 59-TCGAA-
CTCCAAATTTCTACCC-39 (forward) and 59-TGCTTGGTCT
TTATCAACCA-39 (reverse), EphB4 59-CAAAGTATGCAGA
GCCTGTG-39 (forward) and 59-CCGGTAATACCCAATTC-
GAC-39 (reverse). Results were detected based on amplicon
binding of Sybr Green using quantitative RT-PCR and are
representative of at least three independent experiments.
X-ray tomography (XTM)
XTM studies were used to assess the degree of mineralization of
the bone; procedures were based on the work of Kinney et al. [33].
Whole male mouse femora were scanned to determine the degree
of bone mineralization (N=3/group). Imaging was performed at
the Advanced Light Source (ALS) on Beamline (8-3-2) at the
Lawrence Berkeley National Laboratory by obtaining two-
dimensional radiographs as the specimens were rotated through
180u in 0.5u increments. The radiographs were reconstructed into
2,500 slices by Fourier-filtered back projection with a 4.5 mm
resolution. The attenuation coefficient (mm
21) of each pixel relates
directly to bone mineral concentration. The degree of bone
mineralization (DBM) was obtained from Eq. (1):
DBM~
mi{mo
mm{mo
  C ð1Þ
where mi is measured attenuation coefficient at pixel i, mo is the
attenuation coefficient of organic, mm is attenuation coefficient of
mineral, and C represents the density of hydroxyapatite.
Nanoindentation
Dissected male mouse tibiae were embedded in a two-
component epoxy resin (Stycast 1266) prior to sectioning with a
precision low-speed saw to generate mid-tibial cortical bone
surfaces for nanoindentation. A nanoindenter (Triboindenter,
Hysitron, Minneapolis, MN) with a Berkovich tip was used to
evaluate polished samples (0.25 mm) under dry conditions as
described [10]. Indents were applied using a trapezoidal loading
profile with a loading rate of 200 mN/second, peak load of
600 mN, and a hold period of 10 seconds. From the resulting load-
deformation curves, local elastic modulus and hardness were
calculated as described [50]. Three sets of 20 nanoindentation
points were performed in a line with a 5 mm separation. Statistical
analyses show the mean and standard error of the median elastic
modulus values for each of 3 individual animals per group.
Macroscopic mechanical testing
Whole bone strength and load to failure were determined by
mechanical testing of vertebrae and intact tibiae for at least 12
mice per treatment group as previously described [45]. Thawed
bones were hydrated in saline for 1 h before testing at room
temperature using a MTS 858 Bionex Test Systems load frame
(MTS Systems Corp, Eden Prairie, MN). Vertebral bodies (L4)
Table 3. Macromechanical testing of vertebrae.
Male Vertebrae
Vehicle SD-208 60 mg
Peak Load 41.5563.34 54.9565.45*
Stiffness 98.61611.52 111.1618.70
Mean values6SEM for macromechanical tests of vertebral peak load and
stiffness are shown. The significance of differences between vehicle and SD-208
(60 mg/kg) treated groups is indicated with p values (*p,0.05).
doi:10.1371/journal.pone.0005275.t003
Table 4. Macromechanical testing of femora.
Male Femora
Vehicle SD-208 60 mg
Peak Load 16.0960.90 15.5560.52
Stiffness 40.3265.59 47.1061.40
Fracture
Toughness
4.36760.783 4.75560.509
Mean values6SEM for macromechanical tests of femoral peak load, stiffness
and fracture toughness are shown.
doi:10.1371/journal.pone.0005275.t004
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removing the soft cartilage to expose the bone, prior to
compression testing at a rate of 3 mm/minute. Tibiae were tested
in a three-point bending configuration with their anterior side
down on two horizontal supports spaced 7 mm apart; the central
loading point was displaced downward at 0.1 mm/second on the
posterior surface of the diaphysis at the midpoint of the bone
length. For all tests, load-displacement data were recorded at
100 Hz (TestWorks 4.0, MTS). Curves were analyzed to
determine measures of whole-bone strength, primarily peak load
and stiffness [47]. Load-to-failure was recorded as the load after a
2% drop from peak load.
Fracture toughness testing was performed on at least 10 isolated
femora per condition. Thawed samples were notched using a razor
blade followed by a micronotching technique. Notches were
evaluated to ensure that they were through-wall but notched less
than 1/3 of the bone diameter. Samples were tested in 37uC
HBSS in a three-point bending configuration with a custom-made
rig for the ELF 3200 mechanical testing machine (ELF3200, Bose,
EnduraTEC, Minnetonka, MN), in general accordance with
ASTM Standard E-399 and E-1820 [51,52] and as previously
described [53]. Scanning electron microscopy was used to image
fracture surfaces to measure the crack area and point of failure.
The fracture toughness, Kc, was calculated using a stress-intensity
solution for circumferential through-wall flaw in cylinders [43,54].
Macro-mechanical testing was performed on male and female
femora, with no SD-208-dependent differences observed in either
group.
Supporting Information
Figure S1 The diaphysis is not filled by trabecular bone
following SD-208 treatment. Although increased trabecular bone
in femora from SD-208-treated mice (60 mg/kg) is evident in
reconstructed micro-CT images, the trabecualr bone does not
extend past the distal third of the femur. The scale bar is
1 mm.The diaphysis is not filled by trabecular bone following SD-
208 treatment. Although increased trabecular bone in femora
from SD-208-treated mice (60 mg/kg) is evident in reconstructed
micro-CT images, the trabecualr bone does not extend past the
distal third of the femur. The scale bar is 1 mm.
Found at: doi:10.1371/journal.pone.0005275.s001 (1.00 MB TIF)
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